Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

ed net loss per common share for the six

months ended June 30, 2008 and 2007, respectively. Research and

development expense and general and administrative expense includes

$623 and $706 of non-cash operating expenses determined in accordance

with SFAS No. 123R for the six months ended June 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 30, December 31,

2008 2007

(Unaudited) (Audited)

Assets

Cash, cash equivalents and securities

available-for-sale $ 42,112 $ 56,495

Other current assets 1,276 1,004

Noncurrent assets 3,560 4,027

Total assets $ 46,948 $ 61,526

Liabilities and Stockholders' Equity

Current liabilities $ 4,140 $ 5,415

Other long-term liabilities 124 432

Stockholders' equity 42,684 55,679

Total liabilities and

stockholders' equity $ 46,948 $ 61,526


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies ... School of Public Health and New Haven Farms to ... month-long project. The goal of the study was to ... free access to fresh produce and nutrition education on ... high blood pressure, diabetes and weight gain. Patients completed ...
(Date:3/25/2015)... 25, 2015 The surging prevalence ... have fuelled social media growth, with over 50% ... in social networking. Insurance companies are making use ... clients and promote a diversity of their services ... increasingly exploiting social networking services as part of ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
(Date:3/25/2015)... LOUIS and the HAGUE, Netherlands ... of two-year results of LES Stimulation therapy for chronic ... the journal Surgery [ Surgery . ... efficacy of its minimally-invasive therapy. The ... average duration of 11 years and taking prescribed daily ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... , ... responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult ... the FDA in the United States. , ... (PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., ...
... Reportlinker.com announces that a new market research report is available in its catalogue: ... Global Nucleic Acid Testing Industry , ... http://www.reportlinker.com/p0209257/Global-Nucleic-Acid-Testing-Industry.html , , , ... market for Nucleic Acid Testing in US$ Million. Annual estimates and forecasts are provided for ...
... ... ... DuPont biofuels collaborations received top honors in the 2010 “Transformative Technologies 30” survey, conducted ... and the DuPont partnership with Bio Architecture Lab ( BAL ) to develop macroalgae ...
Cached Biology Technology:Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 2Reportlinker Adds Global Nucleic Acid Testing Industry 2Reportlinker Adds Global Nucleic Acid Testing Industry 3Reportlinker Adds Global Nucleic Acid Testing Industry 4Reportlinker Adds Global Nucleic Acid Testing Industry 5Reportlinker Adds Global Nucleic Acid Testing Industry 6Reportlinker Adds Global Nucleic Acid Testing Industry 7Reportlinker Adds Global Nucleic Acid Testing Industry 8Reportlinker Adds Global Nucleic Acid Testing Industry 9Reportlinker Adds Global Nucleic Acid Testing Industry 10DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 2DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 3DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 4
(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... of fat, suggests a new study published in the May ... diet or generated from sugars spark a cascade of gene ... sugar, cholesterol, and other fats, according to the researchers. , ... pathways in motion, they found. The findings in mice suggest ...
... Microtubules are active protein polymers critical to the structure ... division. In a living cell their growing ends constantly ... and depolymerization, like the writhing snakes of Medusa's hair. ... and shrinkage is key to the diverse workings of ...
... development in the U.S. resulted in a reduction of ... ten vaccine-preventable diseases during the twentieth century. These dramatic ... the vaccine system now faces numerous challenges in manufacturing ... May/June issue of Health Affairs. , The U.S. vaccine ...
Cached Biology News:Fat's fate depends on its source 2The making and breaking of microtubules 2The making and breaking of microtubules 3The making and breaking of microtubules 4The making and breaking of microtubules 5Fragile US vaccine system needs improvement despite dramatic gains in health over past century 2Fragile US vaccine system needs improvement despite dramatic gains in health over past century 3
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Biology Products: